|
1）Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999; 53: 1937-42
|
|
|
|
2）Kopf D, Frolich L. Risk of incident Alzheimerʼs disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis. 2009; 16: 677-85
|
|
|
|
|
|
3）Matsuzaki T, Sasaki K, Tanizaki Y, et al. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology. 2010; 75: 764-70
|
|
|
|
|
|
4）Kalaria RN. Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol. 2009; 5: 305-6
|
|
|
|
|
|
5）Sparks DL, Scheff SW, Hunsaker JC 3rd, et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 1994 ;126: 88-94
|
|
|
|
|
|
6）Takeda S, Sato N, Uchio-Yamada K, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010; 107: 7036-41
|
|
|
|
|
|
7）Xu D, Yang C, Wang L. Cerebral amyloid angiopathy in aged Chinese: a clinico-neuropathological study. Acta Neuropathol. 2003; 106: 89-91
|
|
|
|
|
|
8）Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke. 1997; 28: 1418-22
|
|
|
|
|
|
9）Pfeifer LA, White LR, Ross GW, et al. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002; 58: 1629-34
|
|
|
|
|
|
10）Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318: 1315-21
|
|
|
|
|
|
11）Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992; 267: 14987-97
|
|
|
|
|
|
12）Basta G, Lazzerini G, Massaro M, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002; 105: 816-22
|
|
|
|
|
|
13）Sato N, Takeda S, Uchio-Yamada K, et al. Role of Insulin Signaling in the Interaction Between Alzheimer Disease and Diabetes Mellitus: A Missing Link to Therapeutic Potential. Curr Aging Sci. 2011; 4: 118-27
|
|
|
|
|
|
14）Hokama M, Oka S, Leon J, et al. Altered Expression of Diabetes-Related Genes in Alzheimerʼs Disease Brains: The Hisayama Study. Cereb Cortex. 2013 Apr 17. [Epub ahead of print]
|
|
|
|
|
|
15）Janson J, Laedtke T, Parisi JE, et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004; 53: 474-81
|
|
|
|
|
|
16）Bucht G, Adolfsson R, Lithner F, et al. Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med Scand. 1983; 213: 387-92
|
|
|
|
|
|
17）Meneilly GS, Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J Am Geriatr Soc. 1993; 41: 710-4
|
|
|
|
|
|
18）Takeda S, Sato N, Uchio-Yamada K, et al. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun. 2009; 385: 193-7
|
|
|
|
|
|
19）Miklossy J, Qing H, Radenovic A, et al. Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging. 2010; 31: 1503-15
|
|
|
|
|
|
20）Qu Z, Jiao Z, Sun X, et al. Effects of streptozotocin-induced diabetes on tau phosphorylation in the rat brain. Brain Res. 2011; 1383: 300-6
|
|
|
|
|
|
21）Jolivalt CG, Lee CA, Beiswenger KK, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimerʼs disease and correction by insulin. J Neurosci Res. 2008; 86: 3265-74
|
|
|
|
|
|
22）Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, et al. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes. 2006; 55: 3320-5
|
|
|
|
|
|
23）Ke YD, Delerue F, Gladbach A, et al. Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimerʼs disease. PloS One. 2009; 4: e7917
|
|
|
|
|
|
24）Schechter R, Beju D, Miller KE. The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun. 2005; 334: 979-86
|
|
|
|
|
|
25）Kim B, Backus C, Oh S, et al. Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology. 2009; 150: 5294-301
|
|
|
|
|
|
26）Sato N, Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci. 2013; 5: 64
|
|
|
|
|
|
27）Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009; 301: 1565-72
|
|
|
|
|
|
28）Gao L, Matthews FE, Sargeant LA, et al. An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health. 2008; 8: 54
|
|
|
|
|
|
29）Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011; 108: 3017-22
|
|
|
|
|
|
30）Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA. 2008; 300: 1027-37
|
|
|
|
|
|
31）Baker LD, Frank LL, Foster-Schubert K, et al. Aerobic exercise improves cognition for older adults with glucose intolerance, a risk factor for Alzheimerʼs disease. J Alzheimers Dis. 2010; 22: 569-79
|
|
|
|
|
|
32）Liu-Ambrose T, Nagamatsu LS, Graf P, et al. Resistance training and executive functions: a 12-month randomized controlled trial. Arch Intern Med. 2010; 170: 170-8
|
|
|
|
|
|
33）Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011; 10: 969-77
|
|
|
|
|